Article · Wikipedia archive · Last revised Jun 20, 2026

Pimethixene

Pimethixene is an antihistamine and anticholinergic of the thioxanthene chemical class originally developed to treat hyperactivity, anxiety, sleep disorders, and allergy. It is also used for anesthesia and as a bronchodilator.

Last revised
Jun 20, 2026
Read time
≈ 1 min
Length
225 w
Citations
4
Source
Wikipedia ↗
Pimethixene
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral, nasal
ATC code
Identifiers
  • 1-Methyl-4-(9H-thioxanthen-9-ylidene)piperidine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.005.675
Chemical and physical data
FormulaC19H19NS
Molar mass293.43 g·mol−1
3D model (JSmol)
  • S2c1ccccc1/C(c3c2cccc3)=C4/CCN(C)CC4
  • InChI=1S/C19H19NS/c1-20-12-10-14(11-13-20)19-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)19/h2-9H,10-13H2,1H3 checkY
  • Key:NZLVRVYNQYGMAB-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pimethixene is an antihistamine and anticholinergic of the thioxanthene chemical class originally developed to treat hyperactivity,1 anxiety, sleep disorders, and allergy. It is also used for anesthesia and as a bronchodilator (to dilate the bronchi and bronchioles for more airflow).

In combination with pholcodine, it was sold in France by Laboratoires Salvoxyl in the 1970s as the antitussive Salvodex.2 Pimethixene alone is still available in Brazil under the trade name Muricalm.

In addition to its other activities, it is a highly potent but non-selective serotonin 5-HT2B receptor antagonist.3 The selective serotonin 5-HT2B receptor antagonist BF-1 was derived from pimethixene.3

See also

See also

References

References

  1. Chefneux A (July 1978). "[New treatment of hyperkinesis in the child: pimethixene]". Revue Médicale de Liège. 33 (14): 500–3. PMID 674966.
  2. Bailly, Christian (8 December 2020). "Salvodex® (9-(1-methyl, 4-piperylidenyl)thiaxanthene and pholcodine), from Laboratoires Salvoxyl (Orléans), 1971". Oncowitan. Retrieved 4 January 2022.
  3. Schmitz B, Ullmer C, Segelcke D, Gwarek M, Zhu XR, Lübbert H (March 2015). "BF-1--a novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs". Eur J Pharmacol. 751: 73–80. doi:10.1016/j.ejphar.2015.01.043. PMID 25666387.